Literature DB >> 33776920

The Impact of Down-Regulation on Obstetrics and Perinatal Outcomes in Singleton Pregnancies After In Vitro Fertilization.

Lei Jin1, Jihui Ai1, Yu Zheng1, Biao Chen1, Lan Wang1, Xiyuan Dong1.   

Abstract

Background: down-regulation has been widely used in IVF treatment; however, it lacks reports on the impact of down-regulation on obstetrics and perinatal outcomes. The purpose of this study was to compare the obstetrics and perinatal outcomes among different down-regulation conditions.
Methods: this is a retrospective cohort study on 3578 patients achieving cumulative singleton clinical pregnancy after their first oocytes retrieval cycle. Patients were grouped according to the serum estradiol after down-regulation (E2D) into three groups: <30, 30-55, >55 pg/ml. The obstetrics and perinatal outcomes, and live-birth rate per clinical pregnancy were main outcome measures. In the subgroup analysis, patients were further divided according to the mode of transfer. ANOVA, chi-square test, multivariate logistic regression, and multivariate general linear model were performed for statistical analysis.
Results: the patients with E2D <30, 30-55, >55 pg/ml had similar live-birth rates. The patients with E2D <30 pg/ml had a lower risk of hypertension disorders than those with E2D 30-55 pg/ml. No difference was found in the risks of placenta previa, placenta abruption, premature rupture of membrane, hemorrhage, gestational diabetes mellitus, or intrauterine growth restriction. The newborns in the group with E2D <30 pg/ml had a lower risk of PICU admission than those in the group with E2D >55 pg/ml. There was no difference in the risks of congenital anomalies or mortality among the three groups. No differences were found in the gestational week, percentages of preterm birth and very preterm birth, birth weight, percentages of low birth weight and very low birth weight, delivery mode, or sex of newborn. Subgroup analysis showed that E2D 30-55 pg/ml was associated with a higher risk of low birth weight in patients with one fresh transfer + frozen transfer(s).
Conclusion: Down-regulation has no effect on the live-birth rate per clinical pregnancy. Patients with E2D <30 pg/ml may have advantages regarding lower risks of both maternal hypertension and newborn PICU admission. E2D 30-55 pg/ml may be associated with low birth weight in patients with relatively low quality embryos.
Copyright © 2021 Jin, Ai, Zheng, Chen, Wang and Dong.

Entities:  

Keywords:  down-regulation; in vitro fertilization; obstetrics outcomes; perinatal outcomes; singleton pregnancy

Mesh:

Substances:

Year:  2021        PMID: 33776920      PMCID: PMC7988215          DOI: 10.3389/fendo.2021.622081

Source DB:  PubMed          Journal:  Front Endocrinol (Lausanne)        ISSN: 1664-2392            Impact factor:   5.555


  27 in total

Review 1.  In vitro fertilisation: perinatal risks and early childhood outcomes.

Authors:  N R Vulliemoz; E McVeigh; J Kurinczuk
Journal:  Hum Fertil (Camb)       Date:  2012-06       Impact factor: 2.767

2.  Neonatal outcomes after early rescue intracytoplasmic sperm injection: an analysis of a 5-year period.

Authors:  Bo Huang; Kun Qian; Zhou Li; Jing Yue; Wei Yang; Guijin Zhu; Hanwang Zhang
Journal:  Fertil Steril       Date:  2015-03-23       Impact factor: 7.329

3.  The criteria for optimal down-regulation with gonadotropin-releasing hormone-agonist: a retrospective cohort study.

Authors:  Yu Zheng; Xiyuan Dong; Rui Wang; Wei Yang; Hanwang Zhang; Guijin Zhu; Jihui Ai
Journal:  Gynecol Endocrinol       Date:  2015-10-22       Impact factor: 2.260

4.  Transfer of Fresh versus Frozen Embryos in Ovulatory Women.

Authors:  Yuhua Shi; Yun Sun; Cuifang Hao; Heping Zhang; Daimin Wei; Yunshan Zhang; Yimin Zhu; Xiaohui Deng; Xiujuan Qi; Hong Li; Xiang Ma; Haiqin Ren; Yaqin Wang; Dan Zhang; Bo Wang; Fenghua Liu; Qiongfang Wu; Ze Wang; Haiyan Bai; Yuan Li; Yi Zhou; Mei Sun; Hong Liu; Jing Li; Lin Zhang; Xiaoli Chen; Songying Zhang; Xiaoxi Sun; Richard S Legro; Zi-Jiang Chen
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

5.  Reproductive technologies and the risk of birth defects.

Authors:  Michael J Davies; Vivienne M Moore; Kristyn J Willson; Phillipa Van Essen; Kevin Priest; Heather Scott; Eric A Haan; Annabelle Chan
Journal:  N Engl J Med       Date:  2012-05-05       Impact factor: 91.245

6.  Blastocyst culture and transfer: analysis of results and parameters affecting outcome in two in vitro fertilization programs.

Authors:  W B Schoolcraft; D K Gardner; M Lane; T Schlenker; F Hamilton; D R Meldrum
Journal:  Fertil Steril       Date:  1999-10       Impact factor: 7.329

7.  Does IVF cleavage stage embryo quality affect pregnancy complications and neonatal outcomes in singleton gestations after double embryo transfers?

Authors:  Jinliang Zhu; Ying Lian; Ming Li; Lixue Chen; Ping Liu; Jie Qiao
Journal:  J Assist Reprod Genet       Date:  2014-10-18       Impact factor: 3.412

8.  Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome?

Authors:  S Senöz; B Gülekli; N O Turhan; G Ozakşit; A R Odabaşi; H Oral; U Ozcan; O Gökmen
Journal:  Gynecol Endocrinol       Date:  1995-06       Impact factor: 2.260

Review 9.  Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of blastocyst-stage versus cleavage-stage embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis.

Authors:  Abha Maheshwari; Theodoros Kalampokas; Jill Davidson; Siladitya Bhattacharya
Journal:  Fertil Steril       Date:  2013-09-29       Impact factor: 7.329

10.  Live birth sex ratio after in vitro fertilization and embryo transfer in China--an analysis of 121,247 babies from 18 centers.

Authors:  Zhiqin Bu; Zi-Jiang Chen; Guoning Huang; Hanwang Zhang; Qiongfang Wu; Yanping Ma; Juanzi Shi; Yanwen Xu; Songying Zhang; Cuilian Zhang; Xiaoming Zhao; Bo Zhang; Yuanhua Huang; Zhengyi Sun; Yuefan Kang; Riran Wu; Xueqing Wu; Haixiang Sun; Yingpu Sun
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.